EL7.AI
StocksMedium•19 November 2026•
4 min read

Humacyte Files FDA Application for ATEV in Dialysis After 220 Days Without a Catheter

Key Facts

1Mean days free of a catheter were 220 with ATEV versus 129 with a fistula over 12 months of follow-up.
2The application was supported by three Phase 3 studies, including V012, V007 and V006.
3Humacyte announced the supplemental application filing on November 19, 2026.
4The FDA has 60 days to assess whether the application is complete and acceptable for review.

Humacyte announced on November 19, 2026, that it had submitted a supplemental application to the U.S. Food and Drug Administration seeking approval to use its acellular tissue engineered vessel, ATEV, for vascular access in hemodialysis patients with end-stage kidney disease who are at risk of arteriovenous fistula maturation failure. The application seeks to add this use as the product’s second indication, after the agency approved Symvess for treating extremity arterial injuries in December 2024. The submission does not mean ATEV has been approved for hemodialysis; the application now moves into regulatory review. The company said the application is supported by three Phase 3 studies, including V012 and the completed V007 and V006 studies. Humacyte also requested priority review, while the next regulatory step is for the agency to determine whether the application is complete and acceptable for review.

V012 results are central to the clinical case the company is making for the application. In a prespecified interim analysis, mean days free of a catheter were 220 days among ATEV recipients, compared with 129 days among arteriovenous fistula recipients, over 12 months of follow-up. Humacyte’s filing with the U.S. Securities and Exchange Commission said the result met the study’s primary endpoint with statistical significance, with a p-value of 0.00070. The measure tracks the period during which vascular access could be used without relying on a catheter, making the difference between the groups a focus of the reported results. The analysis was conducted after the first 80 enrolled patients completed 12 months of follow-up, in a study planned to include up to 150 patients. After the primary endpoint was met, the V012 protocol called for enrollment to end.

The safety results reported by the company included a comparison of infection rates between the study groups. The ATEV group recorded six infections per 100 patient-years, compared with 23 per 100 patient-years in the arteriovenous fistula group. In the latter group, three infections were access-related, while the company reported no such infections among ATEV recipients. These figures add another measure to V012’s results alongside days free of a catheter, addressing a clinical burden associated with the access used for hemodialysis. The comparison is based on study data as reported in the company’s filing and does not by itself change the regulatory status of the application, which has not yet been approved for the proposed use.

Humacyte defined the target population for the application as adults with end-stage kidney disease who are at risk of arteriovenous fistula maturation failure. The company said about 500,000 Americans currently rely on hemodialysis to survive, indicating the scale of the need it aims to address through the vascular access challenge. Humacyte had previously described its plan to submit the supplemental application in the second half of 2026 in a filing with the U.S. Securities and Exchange Commission, for the same indication. The current announcement falls within that planned period and moves the application from an anticipated filing to regulatory review. But the priority review request and RMAT and Fast Track designations do not amount to approval for the indication; the agency still controls whether the application is accepted and the review timetable.

The product has a regulatory precedent for a different use: The FDA approved Symvess on December 19, 2024, for use in adults as a vascular conduit to treat extremity arterial injuries when urgent revascularization is needed to prevent limb loss and an autologous vein graft is not feasible. The agency said at the time that Symvess was the first approved acellular tissue engineered vessel for this use, and that its earlier application had received priority review and RMAT designation. For the current hemodialysis application, Humacyte says ATEV has received RMAT and Fast Track designations from the FDA. The earlier approval provides regulatory context for the product, but it applies to extremity injuries and does not automatically extend to vascular access for hemodialysis.

Humacyte shares, trading under the symbol HUMA, closed at $0.50 on November 18, 2026, according to EL7 data. That price was for the session before the company announced the application filing on November 19, and does not reflect the market’s reaction to the announcement. After the filing, the FDA has 60 days to determine whether the application is complete and acceptable for review and to set a review timetable. The company requested priority review, but its filing does not say the agency has accepted the application or set a date for a decision. The next near-term step is therefore the agency’s assessment of the application and determination of the review path, before any decision on whether to permit the proposed use.

Open on chart